THE METHOD
Treg method is an innovative Polish breakthrough therapy with T-regulatory cells (Treg) obtained from the patient’s blood. Currently, the therapy is used for the treatment of diabetes type 1 in children. Tregs are unique, small fraction of human lymphocytes, which in the autoimmune diseases, such as diabetes type 1, provide immunoprotection against harmful effects and development of the disease. The uniqueness of the treatment lies in reduction of the disease causes, and not only its clinical symptoms, which improves the quality of life and clinical parameters of pediatric patients.
MISSION
PolTREG’s main goal is the implementation of TREG method on the Polish as well as international market. Due to special character of the biotechnology sector (especially red biotechnology, cell therapies) the so called “time-to-market” is much more time-consuming and capital-intensive in comparison to other sectors – requirement for clinical trials, registration processes for safety and well-being of patients.
Technology
From the medical viewpoint, the therapy process begins with the patient’s diagnosis with type 1 diabetes. After medical assessment in hospital, patient is qualified for the programme. At this point, sampling of venous blood is conducted, which will further serve to isolate white blood cells, and from them TREG cells (regulatory T lymphocytes), which after multiplication in sterile laboratory conditions, are subsequently administered to the same patient as a TREG vaccine.
INVENTORS OF THE TREG METHOD
BOARD MANAGEMENT
Prof. Piotr Trzonkowski
Kamilla Bok
Mariusz Jabłoński
Anna Biegaj
OPERATING TEAM
Dorota Iwaszkiewicz-Grześ, PhD
Mateusz Gliwiński, MSc
Ewa Szmit-Kosińska, PhD
Justyna Sakowska, PhD
Anita Dobyszuk, MSc
Maciej Zieliński, PhD
